tetano
Editor, Senior Moderator
Cell Host Microbe. 2013 Mar 13;13(3):314-23. doi: 10.1016/j.chom.2013.02.008.
Defining influenza a virus hemagglutinin antigenic drift by sequential monoclonal antibody selection.
Das SR, Hensley SE, Ince WL, Brooke CB, Subba A, Delboy MG, Russ G, Gibbs JS, Bennink JR, Yewdell JW.
Source
Laboratory of Viral Diseases, NIAID, Bethesda, MD 20892, USA; Infectious Diseases Group, J. Craig Venter Institute, Rockville, MD 20850, USA; Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA.
Abstract
Human influenza A virus (IAV) vaccination is limited by "antigenic drift," rapid antibody-driven escape reflecting amino acid substitutions in the globular domain of hemagglutinin (HA), the viral attachment protein. To better understand drift, we used anti-hemagglutinin monoclonal Abs (mAbs) to sequentially select IAV escape mutants. Twelve selection steps, each resulting in a single amino acid substitution in the hemagglutinin globular domain, were required to eliminate antigenicity defined by monoclonal or polyclonal Abs. Sequential mutants grow robustly, showing the structural plasticity of HA, although several hemagglutinin substitutions required an epistatic substitution in the neuraminidase glycoprotein to maximize growth. Selecting escape mutants from parental versus sequential variants with the same mAb revealed distinct escape repertoires, attributed to contextual changes in antigenicity and the mutation landscape. Since each hemagglutinin mutation potentially sculpts future mutation space, drift can follow many stochastic paths, undermining its unpredictability and underscoring the need for drift-insensitive vaccines.
Copyright ? 2013 Elsevier Inc. All rights reserved.
PMID:
23498956
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/23498956
Defining influenza a virus hemagglutinin antigenic drift by sequential monoclonal antibody selection.
Das SR, Hensley SE, Ince WL, Brooke CB, Subba A, Delboy MG, Russ G, Gibbs JS, Bennink JR, Yewdell JW.
Source
Laboratory of Viral Diseases, NIAID, Bethesda, MD 20892, USA; Infectious Diseases Group, J. Craig Venter Institute, Rockville, MD 20850, USA; Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA.
Abstract
Human influenza A virus (IAV) vaccination is limited by "antigenic drift," rapid antibody-driven escape reflecting amino acid substitutions in the globular domain of hemagglutinin (HA), the viral attachment protein. To better understand drift, we used anti-hemagglutinin monoclonal Abs (mAbs) to sequentially select IAV escape mutants. Twelve selection steps, each resulting in a single amino acid substitution in the hemagglutinin globular domain, were required to eliminate antigenicity defined by monoclonal or polyclonal Abs. Sequential mutants grow robustly, showing the structural plasticity of HA, although several hemagglutinin substitutions required an epistatic substitution in the neuraminidase glycoprotein to maximize growth. Selecting escape mutants from parental versus sequential variants with the same mAb revealed distinct escape repertoires, attributed to contextual changes in antigenicity and the mutation landscape. Since each hemagglutinin mutation potentially sculpts future mutation space, drift can follow many stochastic paths, undermining its unpredictability and underscoring the need for drift-insensitive vaccines.
Copyright ? 2013 Elsevier Inc. All rights reserved.
PMID:
23498956
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/23498956